DRRSF Financials 07/16/2014 04:05:42 Arianne Phosphate

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
DRRSF Financials 07/16/2014 04:05:42
Arianne Phosphate Inc
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research and Development
Sales, General and Admin.
Non-Recurring Items
Other
Operating Income
Income From Continuing Operations
Add'l Income/Expense Items
Earnings Before Interest and Tax
Interest Expense
Earnings Before Tax
Income Tax
Minority Interest
Equity Earnings Unconsolidated Subsidiary
Net Income Cont. Operations
Non Recurring Events
Discontinued Operations
Extraordinary Items
Effect of Accounting Changes
Other Items
Net Income
Preferred Stock and Other Adjustments
Net Income Applicable to Common Shareholders

D' Arianne Resources (DRRSF) Stock Research Links

DRRSF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Microfluidics Market Growth: Insights and Future Trends

Updated Category News Views 112

Microfluidics Market Overview The global microfluidics market, valued at approximately USD 21.36 billion, is set for impressive growth. Predictions suggest it will reach about USD 32.67 billion by the end of 2029. This significant expansion is a clear indicator of the transformation occurring within diagnostics, life sciences, and pharmaceutical research. Driving Forces...

Continue Reading
How a $1000 Investment in Primerica Can Grow Over Time

Updated Category News Views 333

The Incredible Growth of Primerica Primerica (NYSE: PRI) has truly left a mark in the financial sector, showcasing remarkable performance over the last decade. With an annualized return of 17.97%, it has outperformed the market by 7.08%, demonstrating its strong foundational growth and investment appeal. As of now, Primerica holds a market capitalization of $9.18 billion,...

Continue Reading
Illumina Joins Forces with MyOme: A Game Changer in Healthcare

Updated Category News Views 115

Illumina and MyOme Collaboration Overview Illumina has recently entered into a significant collaboration deal with MyOme, a company specializing in genomic analysis. This partnership isn't just a strategic investment; it's an aerospace-like synergy aimed at transforming how healthcare operates in the United States. With a bold vision, the duo is set to explore innovative...

Continue Reading
BlackSky Technology Secures Major Contract Boosting Stock Appeal

Updated Category News Views 117

BlackSky Technology Gains Momentum After Major Contract Win BlackSky Technology Inc (BKSY) has seen its shares trade higher recently thanks to the remarkable announcement of a five-year contract with the U.S. National Geospatial-Intelligence Agency (NGA). This contract, valued at up to $290 million, will enable BlackSky to leverage its advanced satellite monitoring...

Continue Reading
BioXcel Therapeutics to Showcase Innovations at Conference

Updated Category News Views 255

BioXcel Therapeutics: AI in Medicine BioXcel Therapeutics, Inc. (NASDAQ: BTAI) is making waves in the biopharmaceutical sector using artificial intelligence (AI) to forge new paths in neuroscience medication. The CEO, Vimal Mehta, Ph.D., will take the stage at the highly regarded Canaccord Genuity 45th Annual Growth Conference. This pivotal event will take place in...

Continue Reading